← Leaderboards
Purnima Dubey
Wake Forest University Health Sciences
$5,720,086
Attributed
$13,052,439
Total exposure
9
Grants
6
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $3.1M · FY2007–25$5M$3.8M$2.5M$1.3M$0
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$13,052,439 · 9
By mechanism
R01$11,207,458 · 5
R21$1,187,475 · 3
R56$657,506 · 1
Top collaborators
- Rajendar K Deora16 shared
- Amal O Amer5 shared
- Prosper N Boyaka5 shared
- Stephanie M M Seveau5 shared
- Kenneth Joseph Oestreich2 shared
- Siyuan Ding1 shared
- Jianrong Li1 shared
Most similar at Wake Forest University Health Sciences
Same institution · by research overlap
- Rajendar K Deora$7,651,933
Others in their field
Top investigators on “Immune Response”
- Lawrence Corey · Fred Hutchinson Cancer Center$680,290,567
- Margaret Juliana McElrath · Fred Hutchinson Cancer Center$542,695,345
- Barton F Haynes · Duke University$456,664,915
- Glenda E Gray · Wits Health Consortium (Pty), Ltd$342,310,423
- Gerald T Nepom · Benaroya Research Inst At Virginia Mason$309,708,725
- Peter B. Gilbert · Fred Hutchinson Cancer Center$192,329,665
Research focus
Immune ResponseInfectionAntigensT-LymphocyteImmunityResponseVaccinesT Cell ResponseAdjuvantProteinsCellsPathogenImmunizationLaboratoriesImmunePertussisRespiratory SystemBordetella PertussisCd4 Positive T LymphocytesAntibodiesAcellular VaccinesPhenotypePathogenesisNovel Vaccines
Grant awards (26)
Development of novel multivalent mucosal vaccines for human noroviruses$798,173
R01 · FY2025 · AI
Identification of novel immunogenic proteins from Bordetella pertussis$760,632
R01 · FY2025 · AI · contact PI
Mucosal subunit vaccines against SARS CoV-2$745,036
R01 · FY2025 · AI · contact PI
Host Responses to the Pore-Forming Toxin Listeriolysin O$636,587
R01 · FY2025 · AI
Interaction of Bordetella pertussis with human nasal epithelium$196,875
R21 · FY2025 · AI
Mucosal subunit vaccines against SARS CoV-2$769,833
R01 · FY2024 · AI · contact PI
Identification of novel immunogenic proteins from Bordetella pertussis$760,632
R01 · FY2024 · AI · contact PI
Novel B. Pertussis vaccines that elicit mucosal immunity$657,506
R56 · FY2024 · AI · contact PI
Host Responses to the Pore-Forming Toxin Listeriolysin O$644,081
R01 · FY2024 · AI
Interaction of Bordetella pertussis with human nasal epithelium$236,250
R21 · FY2024 · AI
Identification of novel immunogenic proteins from Bordetella pertussis$760,632
R01 · FY2023 · AI · contact PI
Host Responses to the Pore-Forming Toxin Listeriolysin O$644,081
R01 · FY2023 · AI
Identification of novel immunogenic proteins from Bordetella pertussis$764,867
R01 · FY2022 · AI · contact PI
Host Responses to the Pore-Forming Toxin Listeriolysin O$671,723
R01 · FY2022 · AI
Identification of novel immunogenic proteins from Bordetella pertussis$778,804
R01 · FY2021 · AI · contact PI
Host Responses to the Pore-Forming Toxin Listeriolysin O$594,733
R01 · FY2021 · AI
Acellular TB vaccines adjuvanted with BcfA$234,000
R21 · FY2021 · AI · contact PI
Enhancing efficacy of pertussis vaccines$370,183
R01 · FY2020 · AI · contact PI
Acellular TB vaccines adjuvanted with BcfA$195,000
R21 · FY2020 · AI · contact PI
Enhancing efficacy of pertussis vaccines$370,183
R01 · FY2019 · AI · contact PI
Enhancing efficacy of pertussis vaccines$376,763
R01 · FY2018 · AI · contact PI
Enhancing efficacy of pertussis vaccines$313,973
R01 · FY2017 · AI · contact PI
Enhancing efficacy of pertussis vaccines$55,475
R01 · FY2017 · AI · contact PI
Enhancing efficacy of pertussis vaccines$391,067
R01 · FY2016 · AI · contact PI
Non-invasive imaging of tumor-reactive T cell subsets in vivo$177,600
R21 · FY2008 · CA · contact PI
Non-invasive imaging of tumor-reactive T cell subsets in vivo$147,750
R21 · FY2007 · CA · contact PI